The invention provides well-defined compounds that are either EP
2
agonists, EP
4
agonists, or mixed EP
2
/EP
4
agonist. The compounds are useful for treating a variety of pathological conditions associated with activity of the EP
2
and/or EP
4
receptors.
The invention provides well-defined compounds, including compounds of the following formula, that are either EP2 agonists, EP4 agonists, or mixed EP2/EP4 agonist. The compounds are useful for treating a variety of pathological conditions associated with activity of the EP2 and/or EP4 receptors.